Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Chordate Medical Holding

0,60 SEK

-2,60 %

Mindre end 1K følgere

CMH

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
-2,60 %
-86,67 %
-90,71 %
-90,91 %
-92,39 %
-95,56 %
-99,74 %
-99,61 %
-99,96 %

Chordate Medical Holding is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine, a neuromodulatory and drug-free treatment technique for chronic migraine and chronic rhinitis. The treatment has proven efficacy according to a clinical study and is marketed in selected markets in the EU and the Middle East. The company is headquartered in Kista.

Læs mere
Markedsværdi
1,62 mio. SEK
Aktieomsætning
2,08 t SEK
Omsætning
660 t
EBIT %
-4.159,09 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
5.12
2025

Delårsrapport Q3'25

8.12
2025

Ekstraordinær generalforsamling '25

27.2
2026

Årsrapport '25

Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Selskabsmeddelelse18.11.2025, 18.40

Notice to the Extraordinary General Meeting in Chordate Medical Holding AB (publ)

Chordate Medical Holding
Selskabsmeddelelse18.11.2025, 18.30

The board of directors of Chordate proposes that the general meeting resolves on voluntary liquidation and delisting

Chordate Medical Holding
Selskabsmeddelelse21.8.2025, 06.30

Chordate Announces Cost Reduction and Focus on Company Sale

Chordate Medical Holding

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Pressemeddelelse19.8.2025, 06.30

Chordate reports preliminary conclusions from long-term study on chronic migraine: PM010

Chordate Medical Holding
Selskabsmeddelelse17.7.2025, 13.45

Bulletin from the Extraordinary General Meeting of Chordate Medical Holding AB (publ)

Chordate Medical Holding
Selskabsmeddelelse30.6.2025, 16.45

Notice of Extraordinary General Meeting of Chordate Medical Holding AB (publ)

Chordate Medical Holding
Selskabsmeddelelse30.6.2025, 16.30

Chordate decides on a conditional directed new issue of Preference Shares of approximately SEK 2.55 million

Chordate Medical Holding
Pressemeddelelse27.6.2025, 06.30

Chordate presents conclusions from the second data monitoring of the ongoing open-label long-term study on chronic migraine: PM010

Chordate Medical Holding
Pressemeddelelse27.5.2025, 09.52

BioStock: Chordate Medical’s CEO comments on the quarterly report

Chordate Medical Holding
Selskabsmeddelelse23.5.2025, 06.30

Chordate Medical Holding AB (publ) Interim Report January-March 2025

Chordate Medical Holding
Selskabsmeddelelse21.5.2025, 14.15

Communiqué from the Annual General Meeting of Chordate Medical Holding AB (publ)

Chordate Medical Holding
Pressemeddelelse20.5.2025, 09.00

BioStock: BioStock: New distributor strengthens Chordate Medical’s investment in Saudi Arabia

Chordate Medical Holding
Pressemeddelelse13.5.2025, 08.45

Chordate Medical Expands Migraine Offering in Saudi Arabia – Appoints Additional Distributor

Chordate Medical Holding
Selskabsmeddelelse7.5.2025, 08.55

Chordate Medical terminates the liquidity provider agreement for the preference share

Chordate Medical Holding
Selskabsmeddelelse1.5.2025, 07.00

Change of Certified Adviser (CA) to Bergs Securities

Chordate Medical Holding
Selskabsmeddelelse15.4.2025, 09.15

Notice to the Annual General Meeting in Chordate Medical Holding AB (publ)

Chordate Medical Holding
Pressemeddelelse15.4.2025, 07.28

Chordate Medical Holding: BioStock: Chordate Medical obtains trademark registration for Ozilia in the US

Chordate Medical Holding
Selskabsmeddelelse11.4.2025, 06.30

Chordate Medical Holding AB publishes annual report for 2024

Chordate Medical Holding
Pressemeddelelse10.4.2025, 10.35

Chordate Medical Receives Trademark Registration for Ozilia® in the United States

Chordate Medical Holding
Pressemeddelelse3.4.2025, 08.20

"The treatment makes a big difference for me" – New article in Svenska Dagbladet about Ozilia from Chordate

Chordate Medical Holding
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.